ABSTRACT
Alzheimer’s disease (AD) is a complex degenerative disease of the central nervous system. Traditional epidemiological studies have reported several risk factors for AD. However, most epidemiological studies are insufficient to draw definitive conclusions on causal association due to the potential for reverse causality and confounding bias. Therefore, elucidating its pathogenesis remains challenging. Mendelian randomization (MR) was developed for assessing causality using genetic variants as a new approach in epidemiological research. In this study, we used MR analysis to investigate potential AD risk factors to support extensive AD research. We used the inverse-variance weighted (IVW) model as the major analysis method to perform hypothesis-free Mendelian randomization analysis on the data from MRC IEU OpenGWAS (18,097 exposure traits and 16 AD outcome traits), and conducted sensitivity analysis with six models, to assess the robustness of the IVW results, to identify various classes of risk or protective factors for AD, early-onset AD, and late-onset AD. We generated 400,274 data entries in total, among which the major analysis method of IVW model consists of 73,129 records with 4840 exposure traits, which fall into 10 categories: Disease (n=17,168), Medical laboratory science (n=15,416), Imaging (n=4,896), Anthropometric (n=4,478), Treatment (n=4,546), Molecular trait (n=17,757), Gut microbiota (n=48), Past history (n=668), Family history (n=1,114), and Lifestyle trait (n=7,038). For the convenience of display and operation, an online platform called MRAD has been developed using the Shiny package with MR analysis results. MRAD can be freely accessed online at https://gwasmrad.com/mrad/. Moreover, novel potential AD therapeutic targets (CD33, TBCA, VPS29, GNAI3, PSME1) are identified, among which CD33 was positively associated with the main outcome traits of AD, as well as with both EOAD and LOAD. TBCA and VPS29 were negatively associated with the main outcome traits of AD, as well as with both EOAD and LOAD. GNAI3 and PSME1 were negatively associated with the main outcome traits of AD, as well as with LOAD, but had no significant causal association with EOAD. This is one of the most comprehensive studies in this field. The findings of our research advance understanding of the etiology of AD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the National Natural Science Foundation of China (No. 82302872); the Changchun Science and Technology Planning Project (No. 21ZY18).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
state that source data were openly available before the initiation of the study and they can be located by [MRC IEU OpenGWAS] at (https://gwas.mrcieu.ac.uk/), and [UniProt] at (https://www.uniprot.org/) to all download pages of the original data sources
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Author Biographies: Tianyu Zhao is a PhD student in College of Basic Medical Science, Jilin University. Her research interests include bioinformatics and structural biology. Email: zhaoty22{at}mails.jlu.edu.cn.
Hui Li is a PhD student in Xuanwu Hospital, Capital Medical University. Her research interests include neurology and biology. Email: 3391033864{at}qq.com.
Meishuang Zhang is a lecturer in School of Nursing, Jilin University. Her research interests include pharmacology and epidemiology. Email: zhangmeishuang{at}jlu.edu.cn.
Yang Xu is a postgraduate student in College of Basic Medical Science, Jilin University. His research interests include pharmacology and bioinformatics. Email: yxu22{at}mails.jlu.edu.cn.
Ming Zhang is a professor in College of Basic Medical Science, Jilin University. Her research interests include pharmacology and biology. Email: zhangming_00{at}126.com.
Li Chen is a professor in College of Basic Medical Science, Jilin University. Her research interests include epidemiology and systems biology. Email: chenl{at}jlu.edu.cn.
The newly added text describing the limitations of populations is provided in the Conclusions section (page 19). The newly added text describing more detailed information about the data included data sources and sample selection (in the Data sources section of Methods section, page 8); quality control methods (in the Statistical models for causal effect inference section of Methods section; page 9 to 10). The subheading of the relevant content in the Supplementary Material has been revised to MRAD User Guide (see Supplementary Material for details; page 11). The newly added text describing the practical applications and potential clinical significance of the MRAD database is in the Discussion section (page 15). The newly added text describing more details about each method assumption and the customized best fitted model is in the Statistical models for causal effect inference section of Methods section (page 9 to 10). The newly added text describing the differences and novelty towards previous studies is in the Background section (page 6 to 7). The newly added text describing Bonferroni threshold is in the Statistical models for the causal effect inference section of the Methods section (page 10). We have increased the font size within the graphical abstract figure and enhanced the resolution to improve image readability (page 3). We have now condensed Figures 1 to 8 into a single figure and detailed information of published GWAS have now been added (as shown in Figure 4). We have now displayed the Bonferroni correction results in the sensitivity analysis results figures (as shown in Figure 5; Figure S1 to S7). The sequence of the figures has been adjusted. We have uploaded a main table summarizing robust and consistent exposures for AD that are significant at the Bonferroni threshold and highlight the key results (See Table S2).
DATA AVAILABILITY
Publicly available datasets were analyzed in this study. These data can be found here: [MRC IEU OpenGWAS] at (https://gwas.mrcieu.ac.uk/), and [UniProt] at (https://www.uniprot.org/), the above database search was completed on January 30, 2023.
Abbreviations
- AD
- Alzheimer’s disease
- APP
- amyloid precursor protein
- Aβ
- amyloid-β
- CI
- confidence interval
- EOAD
- early-onset Alzheimer’s disease
- eQTL
- expression Quantitative Trait Loci
- G protein
- guanine nucleotide-binding protein G(k) subunit alpha
- GDP
- guanosine diphosphate
- Gln
- glutamine
- GTP
- guanosine triphosphate
- GWAS
- genome-wide association study
- HLA
- human leukocyte antigen
- IVW
- Inverse Variance Weighted
- LD
- linkage disequilibrium
- LDL
- low density lipoprotein
- LOAD
- late-onset Alzheimer’s disease
- MR
- Mendelian randomization
- MRAD
- Mendelian randomization for Alzheimer’s disease
- OR
- odds ratio
- PSME1
- proteasome activator complex subunit 1
- RCT
- randomized controlled trial
- SIGLECS
- sialic acid-binding immunoglobulin like lectins
- SNPs
- Single nucleotide polymorphisms
- SNXs
- Sorting Nexins
- TBCA
- tubulin-specific chaperone A
- TBCs
- tubulin-specific chaperones
- VLDL
- very low density lipoprotein
- VPS29
- vacuolar protein sorting-associated protein 29
- WHO
- World Health Organization
